Answers are grounded in this paper and cite their sources.
Human papillomavirus (HPV) persistent infection, particularly involving high-risk subtypes, remains the primary driver of cervical cancer, underlining the exigent need for rapid, accessible point-of-care (POC) diagnostics. CRISPR/Cas-based biosensors have developed as transformative tools for POC testing (POCT) because of their exceptional specificity and programmable cleavage activity. This review systematically evaluates HPV biomarkers, including DNA, RNA, and proteins, with a focus on CRISPR/Cas-enabled technologies for POC detection of HPV. We discuss the performance of diverse CRISPR/Cas systems for multiplex biomarker detection in POC settings for HPV infection screening. Recognizing the critical role of signal readout in POCT, we explore several signal-enhancement strategies, including nucleic acid amplification, preamplification-free assays, and integrated platforms tailored to POCT practicality, all aimed at balancing accuracy and practicality. Finally, we address key barriers to clinical translation and propose a roadmap that highlights the emerging role of AI-assisted platforms in advancing multiplexed detection, thereby supporting future decentralized HPV screening and contributing to the global elimination of cervical cancer.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: